PR Newswire Europe - Improvement in Cardiovascular Risk Factors With Rimonabant Demonstrated in Two-Year Study.
ANTWERP, Belgium, March 8 /PRNewswire/ —
- Results from RIO-Europe trial demonstrated that first-year improvements in cardiovascular risk factors are seen through two-year study period
Luc Van Gaal, M.D.
Principal Investigator
RIO-Europe
On behalf of the RIO Steering Committee
Related Results
Cheyenne, Wyo.-area doctors skeptical of ’super bill’ for weight loss, smoking.
Pounds-off prescription
FDA Shouldn’t Approve Diet Drug, Panel Says
Pill could help obesity and smoking.(News)(Brief Article)
Shares in Sanofi fall after anti-obesity drug setback
The results of a two-year phase III study in 1,507 patients treated with rimonabant, the first in a new class of therapeutic agents called selective CB1 Blockers, demonstrated that the improvements in cardiovascular risk factors achieved with rimonabant 20 mg/day at the end of …
Read the rest of this article with a Free Trial at HighBeam Research.
